Journal of Clinical Oncology
Articles in this Issue
Validation of a computational histology artificial intelligence (CHAI) prognostic biomarker in muscle invasive bladder cancer.
791 Background: Standard management for MIBC is radical cystectomy (RC). This traditionally includes neoadjuvant chemother...
Interaction between obesity and vitamin D and testosterone and vitamin D in prostate cancer patients on active surveillance in the PROVENT trial.
401 Background: PROVENT was a multicentre double blind 3x2 placebo controlled phase II trial to evaluate Vitamin D and Asp...
Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.
LBA417 Background: There is no globally accepted standard of care (SOC) for advanced RCC after IO therapy. VEGFR-TKIs are...
Synergistic efficacy of gedatolisib and darolutamide in prostate cancer to overcome resistance to androgen-targeted therapy.
383 Background: The PI3K/AKT/mTOR (PAM) pathway is frequently dysregulated in prostate cancer (PC), often in association w...
Association of ctDNA status with upstaging, pathologic outcomes, and genomic alterations in high-risk NMIBC.
831 Background: The role of circulating tumor DNA (ctDNA) in non–muscle-invasive bladder cancer (NMIBC) remains incomplete...
EV-PRIME: Phase Ib/II study of enfortumab vedotin and pembrolizumab combined with radiotherapy as a bladder-sparing trimodality therapy in muscle invasive bladder cancer.
TPS885 Background: Enfortumab vedotin and pembrolizumab (EVP) combination is highly effective for patients with metastatic...
Quality of life assessment during prostate cancer radionuclide therapy: Updated FACT-RNT psychometric evaluation.
141 Background: The Functional Assessment of Cancer Therapy–Radionuclide Therapy (FACT-RNT) is a 15-item patient-reported...
Prostate cancer in patients with HIV: A multisite retrospective cohort study.
326 Background: Advances in highly active antiretroviral therapy (HAART) have markedly improved the life expectancy of peo...
Genomic and clinical correlates of belzutifan treatment in renal cell carcinoma (RCC): A retrospective analysis of 240 RCC patients.
528 Background: Belzutifan is a HIF-2α inhibitor approved for the treatment of advanced RCC, targeting the hypoxia signali...
RNDO-564-001: A first-in-human, phase 1/1b study of RNDO-564, a bispecific antibody for the treatment of advanced bladder cancer and other tumors associated with Nectin-4 expression.
TPS903 Background: RNDO-564 is a novel CD28 x Nectin-4 bispecific antibody (bsAb) with a high affinity Nectin-4 binding ar...
Cystectomy-free survival following cretostimogene grenadenorepvec in high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ: Results from the phase 3 BOND-003 trial (Cohort C).
741 Background: A significant treatment gap exists for efficacious, well-tolerated bladder-sparing options for patients wi...
Phase 1 safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of pasritamig in Asian population with metastatic castration-resistant prostate cancer (mCRPC).
172 Background: Pasritamig is a first-in-class bispecific antibody T-cell engager that simultaneously binds human kallikre...
Impact of neoadjuvant chemotherapy on outcomes of bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer.
670 Background: NAC (neoadjuvant chemotherapy) has been established as the standard of care for patients with MIBC (muscle...
Genomic landscape of metastatic urothelial cancer in a multicenter Argentine cohort.
789 Background: Metastatic urothelial carcinoma (mUC) is a lethal disease with a heterogeneous genomic landscape. Most ava...
A prospective study exploring genomic correlates of clinical outcome in patients with metastatic castration-sensitive prostate cancer receiving enzalutamide.
244 Background: The genomic landscape of metastatic castration-sensitive prostate cancer (mCSPC) in Asian populations rema...
End-of-life care preferences in penile cancer patients: Shifting patterns and disparities over two decades.
5 Background: Penile cancer (PC) is often diagnosed late, which leads to advanced disease. Studies have reported that less...
Effect of censorship in the interpretation of outcomes of the enfortumab vedotin plus pembrolizumab EV-302 phase 3 randomized clinical trial.
781 Background: The purpose of this study was to assess whether the high treatment discontinuation rate in the chemotherap...
Plant-based dietary indices and quality of life in men with prostate cancer.
356 Background: Prostate cancer is the most prevalent malignancy among US males, with >3.1 million survivors nationally...
Safety and efficacy of platinum-based neoadjuvant chemotherapy with gemcitabine at 800 mg/m <sup>2</sup> vs. 1000 mg/m <sup>2</sup> in muscle-invasive bladder cancer: A multicenter retrospective study.
773 Background: Platinum-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the gold standard tre...
Predictive capability of combining ExoDx (EPI) and pre-biopsy prostate MRI in detecting clinically significant prostate cancer in African American men.
316 Background: Prostate cancer is the second most common cancer in men and is disproportionately prevalent among African...
Differential quality of life (QoL) with novel hormonal therapy (NHT) in metastatic castration-sensitive prostate cancer (mCSPC): A network meta-analysis of randomized clinical trials.
360 Background: Adding NHT to androgen deprivation therapy (ADT) improves survival in mCSPC, but their comparative impact...
IZABRIGHT-Bladder01: A randomized, open-label, phase 2/3 trial of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), vs platinum-based chemotherapy (PBC) for patients (pts) with advanced urothelial cancer (aUC) and disease progression on or after immunotherapy.
TPS883 Background: While ADC + immunotherapy has been transformative as first-line therapy for aUC, treatment options are...
Phase 1/2 dose escalation/expansion study of REGN10597 (anti–PD-1–IL2Rα-IL2) in patients with advanced solid tumors.
TPS578 Background: Interleukin 2 (IL-2) is a cytokine involved in lymphocyte expansion and differentiation during the anti...
Serum IgG: A novel biomarker for efficacy and prognosis in metastatic clear cell renal cell carcinoma patients receiving first-line immunotherapy combined with tyrosine kinase inhibitors.
445 Background: The first-line use of immunotherapy in combination with tyrosine kinase inhibitors (IO-TKIs) significantly...
Detection of bone metastases in men with low PSA biochemical recurrence of prostate cancer with <sup>18</sup> F-flotufolastat PET/CT: A post-hoc analysis from the phase 3 SPOTLIGHT study.
31 Background: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) has become the mainst...